Респираторная медицина. Руководство (в 2-х томах) - Чучалин А. Г. - Страница 320

12.Littlewood JM. European cystic fibrosis society consensus on standards--a roadmap to "best care".// J Cyst Fibros. 2005 Mar;4(1):1-5. Epub 2005 Jan 25

13.Littlewood JM. Good care for people with cystic fibrosis.// Paediatr Respir Rev. 2000 Jun;1(2):179-89

14.Амемлина Е.Л.,Чучалин А.Г. Муковисцидоз, современный подход к диагностике и лечению.//Рус.Мед.Ж.., 1997. т.5, 17:1136-1142.

15.Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003.//Eur Respir J. 2007 Mar;29(3):522-6

16.Иващенко Т.Э., Баранов В.С. Биохимические и молекулярно-генетические основы патогенеза муковисцидозаю //Спб.: «Интермедика», 2002 - С.256.

17.Tsui L-C, Buchwald M: Biochemical and molecular genetics of cystic fibrosis. //Adv Hum Genet 20:153-266, 1991.

18.Riordan JR, Rommens JM, Kerem B-T, et al: Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. //Science 245:1066-1073, 1989.

19.Kerem E, Corey M, Kerem B-S, et al: The relation between genotype and phenotype in cystic fibrosis: Analysis of the most common mutation (DF508).// N Engl J Med 323:1517-1522, 1990

20.. Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2002. Bethesda, MD: Cystic Fibrosis Foundation, 2003Капранов Н.И., Каширская Н.Ю. Актуальные проблемы муковисцидоза на современном этапе в России.// Пульмонология, 1997 4:7-16.

22.Report of a Joint Meeting. The molecular Genetic Epidemioilogy of Cyctic Fibrosis//WHO/HGN/CF/WG/04.02. P.15

23.Davis PB. Cystic fibrosis since 1938.//Am J Respir Crit Care Med. 2006 Mar ;173(5):475-82

24.Амелина Е.Л, Черняк А.В, Черняев А.Л.. Муковисцидоз: определение продолжительности жизни // Пульмонология - 2001 - 3 - С.61-64

25.. Zielenski J, Tsui LC: Cystic fibrosis: Genotypic and phenotypic variations.// Annu Rev Genet 29:777-807, 1995

26. Engelhardt JF, Yankaskas JR, Ernst SA, et al: Submucosal glands are the predominant site of CFTR expression in human bronchus.// Nat Genet 2:240-247, 1992

27.Gregory RJ, Cheng SH, Rich DP, et al: Expression and characterization of the cystic fibrosis transmembrane conductance regulator.// Nature 347:382-386, 1990.

28.Davis PB: Pathophysiology of the lung disease in cystic fibrosis. In Cystic Fibrosis (Lung Biology in Health and Disease), vol 64. New York: Marcel Dekker, 1993, pp 193-218.

29.Welsh M.J., Smith A.E.: Molecular mechanisms of CFTR chloride channel dysfunction in cys . tic fibrosis.// Cell., vol.73:1251-1254.

30. Knowles MR, Friedman KJ, Silverman L: Genetics, diagnosis, and clinical phenotype. In Cystic Fibrosis in Adults. Philadelphia: Lippincott-Raven, 1999, pp 27-42

31.Gradient of distribution in Europe of the major CF mutation and of its associated haplotype. European Working Group on CF Genetics (EWGCFG).//Hum Genet. 1990 Sep;85(4):436-45.

32.Baranov VS, Ivaschenko TE, Gorbunova VN,et al. Frequency of the F508 deletion in cystic fibrosis patients from the European part of the USSR.//Hum Genet. 1991 May;87(1):61-4.

33.Lerer I, Cohen S, Chemke M,et al.. The frequency of the delta F508 mutation on cystic fibrosis chromosomes in Israeli families: correlation to CF haplotypes in Jewish communities and Arabs.//Hum Genet. 1990 Sep;85(4):416-7.

34.Watson EK, Mayall ES, Simova L, et al. The incidence of delta F508 CF mutation, and associated haplotypes, in a sample of English CF families. //Hum Genet. 1990 Sep;85(4):435-6

35.Koch C, Cuppens H, Rainisio M, et al.. European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations.//Pediatr Pulmonol. 2001 Jan;31(1):1-12.

36.Капранов Н.И., Шабалова Л.А., Каширская Н.Ю. и др. Муковисцидоз (современные достижения и проблемы). Методические рекомендации. М.: Медпрактика 2005. С.76

37.Dulhanty AM, Chang XB, Riordan JR., Mutation of potential phosphorylation sites in the recombinant R domain of the cystic fibrosis transmembrane conductance regulator has significant effects on domain conformation.//Biochem Biophys Res Commun. 1995 Jan 5;206(1):207-14.

38.Chang XB, Hou YX, Jensen TJ, Riordan JR., Mapping of cystic fibrosis transmembrane conductance regulator membrane topology by glycosylation site insertion.//J Biol Chem. 1994 Jul 15;269(28):18572-5.

39.Davis PB., Molecular and cell biology of cystic fibrosis.//,J Appl Physiol. 1991 May;70(5):2331-3.

40.Knowles MR, Robinson JM, Wood RE, et al: Ion composition of airway surface liquid of patients with cystic fibrosis as compared to normal and disease-control subjects. //J Clin Invest 100:2588-2595, 1997.

41.Berger HA, Travis SM, Welsh MJ: Regulation of the cystic fibrosis transmembrane conductance regulator Cl- channel by specific protein kinases and protein phosphatases.// J Biol Chem 268:2037-2047, 1993

42.Smith J.J., Travis S.M., Greenberg E.P., Welsh M.J. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. //Cell. 196; 85: 229-236.

43.Bonfeld T.L., Konstan M.W., Burfeind P. et al. Normal bronchial epitheliual cells constitutely produce the anti-inflammatory cytokine IL-10 which is down-regulated in cystic fibrosis.//Am. J. Resp. Cell Mol. Biol. 1995; 13: 257-261.

44.Sommerhof C.P., Nadel J.A., Basbaum C.B., Caughey G.H. Neutrophil elastase and catepsin G stimulate secretion from cultures bovine airway glands.// J. Clin. Invest. 1990; 85: 682-689.

45.Berger M., Sorensen R.U., Tosi M.F. et al. Complement receptor expression on neutrophils at the inflammatory site, The Pseudomonas-infected lung in cystic fibrosis.// J. Clin. Invest. 1989; 84: 1302-1313.

46.De Rose V. Mechanisms and markers of airway inflammation in cystiv fibrosis.//Eur. Resp. J. 2002; 19: 333-340.

47.Matsui H., Grubb B.R., Tarran R.et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. //Cell. 1998; 95: 1005-1015.

48.Guggino W.B. Cystic fibrosis and the salt conroversy. //Cell. 1999; 96: 607-610.

49.Кучкина Н.В., Самсонова М.В. Влияние осмотичности среды на морфофункциональное состояние нейтрофилов крови при муковисцидозе. //Пульмонология. 1996; 4: 77-79.

50.Leid JG, Willson CJ, Shirtliff ME, Hassett DJ, Parsek MR, Jeffers AK. The exopolysaccharide alginate protects Pseudomonas aeruginosa biofilm bacteria from IFN-gamma-mediated macrophage killing.// J Immunol. 2005 Dec 1;175(11):7512-8

51.Ornoy A., Arnon J., Katznelson D. et al. Pathological confirmation of cystic fibrosis in the fetus following prenatal diagnosis.// Am. J. Med. Genet. 1987; 28: 935-947.

52.Oppenheimer E.H., Esterly J.R. Pathology of cystic fibrosis; review of literature and comparison of 146 autopsied cases.// Perspect. Pediatr. Pathol. 1975; 2: 241-278.

53.Sheppard M.N. The pathology of cystic fibrosis. In: Cystic fibrosis./ Eds. M.E. Hodson and D.M. Geddes. Chapman & Hall Medical. London. 1997: 131-149.

54.Bedrossian C.W., Greenberg S.D., Singer D.B. et al. The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups.// Hum. Pathol. 1976; 7: 195-204.

55.Tomashefski J.F., Dahms B., Bruce M. Pleura in pneumothorax. Comparison of patients with cystic fibrosis and idiopatic spontaneous pneumothorax. //Arch. Patholl. Lab. Med. 1985. 109: 910-916.

56.Зашихин А.Л., Агафонов Ю.В., Заостровская Л.А., Черняев А.Л., Быков В.П. Морфофункциональная организация гладкой мышечной ткани бронхов различных генераций у человека // Пульмонология.- 1997.- 3.- С.61-64.

57.Guidotti T.L., Luetzeker J., di Sant’Agnese P.A. et al. Fatal disseminated aspergollosis in a previously well young adult with cystic fibrosis.// Am. J. Med. Sci. 1982; 282: 157-160.

58.Bhargava V., Tomashefski J.F., Stern R.C., Abramovsky C.R. The pathology of fungal infection and colonization in patients with cystic fibrosis.// Hum. Pathol. 1989; 20: 977